TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32897236
Drug: Biannual topical
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual topical application of silver diamine fluoride
Study: 32897236
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment + biannual fluoride varnish
Study: 32900761
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in medication purchases (painkillers and indigestion medication) 10-12 months before ovarian cancer diagnosis
Study: 32901324
Drug: Serum lipase
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum lipase > 51 U/L on POD3
Study: 32901324
Drug: IL-6 >
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 > 56.5 ng/l on POD3
Study: 32901324
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of serum lipase and IL-6 on POD3
Study: 32902099
Drug: Oral Anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Anticoagulation Therapy (OAT)
Study: 32903035
Drug: Radiopharmaceutical administrations
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiopharmaceutical administrations during diagnostic nuclear medicine procedures
Study: 32903035
Drug: Detailed analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detailed analysis of radiation dose calculations
Study: 32903199
Drug: Convalescent Plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent Plasma (CP) infusion
Study: 32903267
Drug: Karate intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Karate intervention (10-week, twice weekly classes)
Study: 32903394
Drug: Dance Movement
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dance Movement Therapy (DMT) + Treatment as Usual (TAU)
Study: 32903594
Drug: First-Line Treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-Line Treatment
Study: 32903623
Drug: Personalized medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized medicine intervention
Study: 32904162
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg + Ezetimibe 10 mg (R/E)
Study: 32904162
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg + Ezetimibe 10 mg (S/E)
Study: 32904162
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg + Ezetimibe 10 mg (R/E)
Study: 32904162
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg + Ezetimibe 10 mg (S/E)
Study: 32905674
Drug: Recombinant factor
Normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant factor VIII at a dose of 25 IU/kg
Study: 32905674
Drug: Recombinant factor
Normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant factor VIII at a dose of 65 IU/kg
Study: 32905674
Drug: BIVV001 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIVV001 at a dose of 65 IU/kg
Study: 32907357
Drug: Hydroxychloroquine 400
Normalized name: hydroxychloroquine 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 400 mg daily during pregnancy
Study: 32907766
Drug: Mindfulness therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness therapy applied to experimental group patients
Study: 32907766
Drug: Mindfulness therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness therapy (experimental group)
Study: 32907782
Drug: Sacral neuromodulation
Normalized name: Boswellia sacra whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacral neuromodulation (SNM) therapy with the InterStim™ system
Study: 32907899
Drug: Individual-level factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual-level factors (e.g., walking distance to health facility, ANC visits, last birth at health facility, number of children, knowledge on FP, intentions to use FP)
Study: 32907899
Drug: Community-level factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-level factors (e.g., electronic media possession, women's decision making on FP)
Study: 32908559
Drug: Ultrasound-guided percutaneous
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided percutaneous needle electrolysis (PNE) in combination with an eccentric exercise program
Study: 38330045
Drug: Same-day initiation
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day initiation (SDI) of antiretroviral therapy (ART)
Study: 32910099
Drug: High-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose spinal cord stimulation (HD-SCS)
Study: 32910151
Drug: Doxorubicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin plus pembrolizumab (45 and 75 mg/m2)
Study: 32910776
Drug: rs738409(G) SNP
Normalized name: SNP-ACTH (1-39)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rs738409(G) SNP variant
Study: 32912180
Drug: Melatonin 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 1, 2, or 4 mg granules orally
Study: 32912664
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (WP) monotherapy
Study: 32913286
Drug: sapanisertib 5
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sapanisertib 5 mg QD
Study: 32913286
Drug: sapanisertib 40
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sapanisertib 40 mg QW
Study: 32913286
Drug: sapanisertib 30
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sapanisertib 30 mg QW
Study: 32913985
Drug: RNA-seq classifiers
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNA-seq classifiers for hormone responsiveness
Study: 32913985
Drug: MGC hormone-responsive
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MGC hormone-responsive classifier
Study: 32914038
Drug: Experimental arms
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental arms of innovative glioblastoma therapy
Study: 32914038
Drug: Standard concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard concurrent temozolomide and radiation therapy followed by adjuvant temozolomide (Control)
Study: 32914172
Drug: Levonorgestrel-releasing intravaginal
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel-releasing intravaginal ring (IVR) delivering 40 µg LNG per day
Study: 32914187
Drug: BDG concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDG concentration >100 pg/mL
Study: 32914187
Drug: Multiple (≥2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple (≥2) positive results >100 pg/mL or a BDG concentration increasing >100 pg/mL
Study: 32914187
Drug: BDG concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDG concentration >100 pg/mL in patients with IC
Study: 32914187
Drug: BDG concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDG concentration ≤100 pg/mL in patients with IC
Study: 32914187
Drug: BDG concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDG concentration >100 pg/mL in patients without IC
Study: 32914581
Drug: Desmopressin 25-μg
Normalized name: desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin 25-μg ODTs
Study: 32914581
Drug: Desmopressin 50-μg
Normalized name: desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin 50-μg ODTs
Study: 32914581
Drug: Desmopressin ODTs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin ODTs (25 and 50 μg)
Study: 32915384
Drug: Daratumumab subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab subcutaneous (DARA SC) 1,800 mg
Study: 32915419
Drug: Crenigacestat (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenigacestat (75 mg escalating to 150 mg TIW for 2 weeks, then 50 mg TIW) + Prednisone (co-administered for 2 weeks in Cycle 1)
Study: 32915419
Drug: Crenigacestat (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenigacestat (75 mg TIW)
Study: 32915419
Drug: Crenigacestat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenigacestat (100 mg BIW)
Study: 32915679
Drug: CaboNivo (cabozantinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaboNivo (cabozantinib 40 mg/d plus nivolumab 3 mg/kg)
Study: 32915679
Drug: CaboNivoIpi (cabozantinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaboNivoIpi (cabozantinib 40 mg/d, nivolumab 3 mg/kg, and ipilimumab 1 mg/kg)
Study: 32916296
Drug: Tiotropium +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium + Olodaterol fixed-dose combination (5 μg/5 μg)
Study: 32916310
Drug: Almonertinib (HS-10296)
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almonertinib (HS-10296) at doses of 55, 110, 220 mg
Study: 38171926
Drug: Liver-directed gene
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver-directed gene therapy
Study: 32917192
Drug: 37.5% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5% hydrogen peroxide gel
Study: 32917626
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of elevated serum ACE and lymphopaenia
Study: 32917626
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of elevated serum ACE and lymphopaenia in patients aged ≤50 years
Study: 32917626
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of elevated serum ACE and lymphopaenia in granulomatous uveitis
Study: 32918045
Drug: SAF-189s, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAF-189s, a new-generation ROS1/ALK inhibitor
Study: 32918045
Drug: Crizotinib (first-generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib (first-generation ROS1 inhibitor)
Study: 32919178
Drug: apixaban 10
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: apixaban 10 mg bid for seven days, then 5 mg bid for six months
Study: 32919458
Drug: Discordant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discordant therapy
Study: 32919527
Drug: Intramuscular extended-dose
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular extended-dose fulvestrant 500 mg (Cohort A)
Study: 32919527
Drug: Oral neratinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral neratinib 240 mg and intramuscular standard-dose fulvestrant (Cohort B)
Study: 32919527
Drug: Oral capivasertib
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capivasertib 400 mg plus intramuscular standard-dose fulvestrant (Cohort C)
Study: 32919527
Drug: Oral capivasertib
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capivasertib 480 mg (Cohort D)
Study: 32920453
Drug: Epworth Sleepiness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epworth Sleepiness Scale (ESS) after PAP therapy
Study: 32920652
Drug: Residual drug
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual drug level (RDL) feedback from counselors
Study: 32921507
Drug: Pentacel vaccine
Normalized name: PENTACEL VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentacel vaccine (Group 1)
Study: 32921507
Drug: Other brand
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other brand of vaccine (Group 2)
Study: 32922454
Drug: Electronic monitoring
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic monitoring combined with IMS-based weekly feedback and reminders
Study: 32922827
Drug: Renal denervation
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal denervation (treatment group)
Study: 32923156
Drug: TIL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIL therapy alone
Study: 32923156
Drug: Cyclophosphamide/fludarabine preconditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide/fludarabine preconditioning and intravenous IL-2 after TIL transfer
Study: 32923156
Drug: DC vaccine
Normalized name: Recombinant chimeric COVID-19 DC vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC vaccine (five intradermal injections)
Study: 32923921
Drug: LA-rich vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA-rich vegetable oil (10 mL/d)
Study: 32924093
Drug: SM-88 (230
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM-88 (230 mg BID), methoxsalen (10 mg), phenytoin (50 mg), sirolimus (0.5 mg)
Study: 32924568
Drug: Fast-Acting Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-Acting Insulin Aspart
Study: 32925563
Drug: Autologous dendritic
Normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous dendritic cells transduced with AdGMCA9 (DC-AdGMCAIX) injected intradermally at doses of 5, 15, and 50×10 cells/administration, every 2 weeks for 3 doses.
Study: 32927016
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of orange juice (OJ)
Study: 32928136
Drug: Salvage chemoradiation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage chemoradiation therapy (CRT)
Study: 32928264
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy and palbociclib
Study: 32928517
Drug: Epinephrine administration
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine administration before ICU admission
Study: 32928701
Drug: 1-hour glucose
Normalized name: glucose 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour glucose (1hG) ≥155 mg/dL
Study: 32928795
Drug: Pomalidomide, low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide, low-dose dexamethasone (LoDEX), and daratumumab
Study: 32928796
Drug: Flumatinib 600
Normalized name: Flumatinib
DrugBank: Flumatinib (DB11904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumatinib 600 mg once daily
Study: 32928858
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) treatment initiated prior to 20 weeks gestation, cessation of TDF 1 month after delivery.
Study: 32928858
Drug: Monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring of adverse events including risk of flare and adherence based on pill count and questionnaire.
Study: 32931398
Drug: Ibrutinib at
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib at 420 mg/d
Study: 32931710
Drug: Risk medication
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk medication usage
Study: 32931710
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPIs) usage
Study: 32933874
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon (DCB) in combination with a new-generation drug-eluting stent (DES)
Study: 32934619
Drug: 3% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% prilocaine with 3% felypressin (0.03 I.U. per ml)
Study: 32934722
Drug: TPF induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF induction chemotherapy in patients with high cyclin D1 expression (cN2 stage)
Study: 32936949
Drug: Antimicrobial mouthwashes
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial mouthwashes and nasal sprays (e.g., povidone iodine, nitric oxide, GLS-1200 oral spray)
Study: 32936949
Drug: Antimicrobial mouthwashes
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial mouthwashes and nasal sprays
Study: 32936949
Drug: Antimicrobial mouthwashes
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial mouthwashes and nasal sprays (if administered to patients)
Study: 32938595
Drug: Prescribing rates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribing rates across medication classes used in AD (emollients, topical corticosteroids by potency, topical calcineurin inhibitors, topical antimicrobials, antihistamines, oral corticosteroids, and systemic immunomodulatory therapies).
Study: 32938595
Drug: Treatment escalation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment escalation in people first diagnosed with AD during the study period, analyzed using time-to-event analysis.
Study: 32939459
Drug: Ledipasvir 90
Normalized name: ledipasvir 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir 90 mg plus sofosbuvir 400 mg (daily for 12 weeks)
Study: 32939607
Drug: Crenigacestat 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenigacestat 25 mg, administered orally 3 times per week over a 28-day cycle
Study: 32939607
Drug: Crenigacestat 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenigacestat 50 mg, administered orally 3 times per week over a 28-day cycle
Study: 32940955
Drug: N8-GP (turoctocog
Approvals — FDA: no, EMA: no, PMDA: no
Description: N8-GP (turoctocog alfa pegol) 60 IU/kg, twice-weekly for 50 exposure days (~26 weeks)
Study: 32940955
Drug: N8-GP (turoctocog
Approvals — FDA: no, EMA: no, PMDA: no
Description: N8-GP (turoctocog alfa pegol) 60 IU/kg, twice-weekly for a median time of ~4.9 years
Study: 32941876
Drug: Plasma cadmium
Normalized name: cadmium
DrugBank: Cadmium (DB14085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma cadmium levels (58 ng/L median)
Study: 32943098
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg/month for 7 infusions)
Study: 32943160
Drug: Recommended dosing
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended dosing of DOACs
Study: 32943160
Drug: Nonrecommended dosing
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonrecommended dosing of DOACs (combined underdosing and overdosing)
Study: 32943286
Drug: Donor-specific antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor-specific antibodies
Study: 32943410
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (patients not receiving antifibrotic therapy)
Study: 32945202
Drug: Intravenous dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dipyridamole (DP)
Study: 32945596
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg/day for ≥ 2 weeks
Study: 32945596
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of ethinylestradiol (EE) 30 μg and levonorgestrel (LN) 150 μg
Study: 32945596
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of bupropion (75 mg) and midazolam (2 mg)
Study: 32946725
Drug: Antiretroviral therapy-naive
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy-naive patients
Study: 32947291
Drug: 20% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% albumin with lactated Ringer's solution
Study: 32949123
Drug: Cognitive Functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Functional Therapy (CFT) for 14 weeks
Study: 32949150
Drug: Regorafenib treatment
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib treatment
Study: 32949176
Drug: Anlotinib 12
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 12 mg p.o. once every day (days 1-14, with a 21-day cycle)
Study: 32949176
Drug: Oral temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral temozolomide chemotherapy 100 mg/m²
Study: 32949828
Drug: Re-biopsy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-biopsy after first line treatment
Study: 32950058
Drug: Eculizumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab treatment during kidney transplantation
Study: 32950419
Drug: Prasugrel monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel monotherapy for 3 months
Study: 32951151
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma administered early in the disease course (severe illness group)
Study: 32951684
Drug: Personalized dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized dose of fish oil (mean target dose 6.63 g/day to 4.06 g/day)
Study: 32951684
Drug: Dynamic modeling
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic modeling of fish oil dosing
Study: 32951684
Drug: Bayesian design
Normalized name: Babesia microti preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bayesian design for dosing algorithm